source
- Celldex's barzolvolimab meets Phase 3 goals but safety concerns emergeCelldex announced that its experimental chronic hives treatment, barzolvolimab, achieved the primary endpoint in two Phase 3 trials. The trials demonstrated the drug's efficacy in reducing hive sy…
- Nvidia-backed Iambic Therapeutics files for IPO, unveils AI-driven pipelineIambic Therapeutics, a San Diego biotech that uses artificial intelligence to discover medicines, announced it has filed a registration statement to become a publicly traded company. The filing ma…